Table 1. . Summary of viruses that have been developed as oncolytic vectors with a brief overview of some strategies implemented for tumor-specific targeting, increasing efficacy and immune evasion.
Genome | Family | Virus | Natural host | Targeting properties | Arming/immune evasion | Example malignancies targeted | Ref. |
---|---|---|---|---|---|---|---|
RNA | Coronaviridae | Mouse Hepatitis Feline Infectious Peritonitis |
Mice Felines |
Bispecific adapter | None | Glioma, EGFR(+) cancers, etc. | [14,15] |
Orthomyxoviridae | Influenza A | Birds, swine, humans, etc. | Deletion of NS1, IFN defects, α-2,3-linked glycan receptor | IL-15/multiple HA, NA configurations | Melanoma, pancreatic adenocarcinoma, etc. | [16,17] | |
Paramyxoviridae | Measles Mumps New Castle disease |
Humans Humans Birds |
scFy, DARPins ligands, protease-dependent activation, miRNA targetsCD46/SLAM/Nectin-4/sialic acid expression, IFN defects, apoptosis defects | NIS, GM-CSF, IL-2. TNFα, NAP, PNP, anti-PDL1, anti-CTLA4, IFNβ/pseudotyping, glycan shield, coating | Multiple myeloma, lymphoma, acute myeloid leukemia, ovarian, breast, glioblastoma, prostate, mesothelioma, etc. | [11,18–24] | |
Picornaviridae | Coxsackie A21 Mengo Polio Seneca Valley |
Humans Rodents Humans Swine, cattle |
miRNA targets, IRES translational control ICAM1 and CD155 expression | None/serotype switching, capsid psuedotyping | Multiple myeloma, melanoma, glioma, neuroendocrine tumors, etc. | [25–27] | |
Reoviridae | Reovirus | Humans | Constitutive Ras signaling | None/multiple serotypes | Pancreatic adenocarcinoma, glioma, prostate, multiple myeloma, melanoma, etc. | [28] | |
Retroviridae | Moloney Murine Leukemia | Mice | S-phase dependent Integration, Tissue-specific promoter, Antibody targeted | Cytosine deaminase/Nonlytic | Glioma, prostate, breast cancer, etc. | [29–32] | |
Rhabdoviridae | Vesicular stomatitis | Horse, cattle, swine, rodents, arthropods | M protein mutants, miRNA targets, tumor targeting ligands IFN defects |
IFNβ, IFNγ Tumor-associated antigen, NIS, TK, cytosine deaminase, IL-4, IL-12, IL-23/anti-Fab aptamers, pseudotyping, PEGylation |
Acute myeloid leukemia, multiple myeloma, melanoma, various solid tumors, etc. | [8,33–38] | |
Togavirdae | Semliki forest Sindbis |
Rodents, Arthropod Birds, Arthropod |
miRNA targets, laminin expression, IFN defects | IL-12, tumor-associated antigen | Cervical, colon, glioma, osteosarcoma, neuroblastoma, etc. | [39–42] | |
DNA | Adenoviridae | Adenovirus C | Humans | Deletion of E1b-55kDa or E1a, tumor-specific promotor, tumor targeting ligands, scFy | HSP, TK, NIS, IL-4, IL12-, IL-18, GM-CSF/serotype switching, polymer shielding | Head and neck, pancreatic, prostate, lung, osteosarcoma, ovarian, bladder, etc. | [43–47] |
Herpesviridae | Herpes simplex 1 Bovine herpes |
Human Cattle |
Deletion of ICP6, γ34.5 and UL39 glycoprotein modification, nestin promotor, miRNA targets, scFy | GM-CSF, ICP47 deletion, IL-4, IL-10, IL-12, TK, rat CYP450 | Glioma, melanoma, breast, ovarian, prostate, colon pediatric solid tumors, etc. | [48–54] | |
Parvoviridae | H1 | Rodents | Viral P4 promotor, S-phase dependent | IL-2 | Glioma, neuroectodermal, lymphoma, pancreatic, gastric, colon, etc. | [55,56] | |
Poxviridae | Myxoma vaccinia |
Rabbit Human |
TK deletion, spi-1 and spi-2 deletion, scFy | GM-CSF, NIS, cytosine deaminase, BMP-4 | Acute myeloid leukemia, multiple myeloma, glioma, Hepatocellular carcinoma, melanoma, lung, pediatric solid tumors, etc. | [57] |
AML: Acute myeloid leukemia; IRES: Internal ribosome entry site.